COMP <GO>
CVM vs BSEM // REVENUE GROWTH (YOY)
Cel-Sci Corporation (NYSE) VS. BioStem Technologies Inc. (NASDAQ) • 15-METRIC TALLY: CVM 2
— BSEM 2
■ METRIC PARITY
LAST: $1.50 (-6.25%) • MKT CAP: $26.4M
revenue-growth
—
LAST: $1.29 (-14.57%) • MKT CAP: $24.1M
revenue-growth
-31.80%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CVM VS. BSEM)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CVM | BSEM | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 93.60% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -5.70% | -29.30 | BSEM | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -1.50% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -13.90% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | — | -31.80% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 2.44 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 5/9 | -2.00 | BSEM | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 36.0 | 21.9 | +14.01 | CVM | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $26.4M | $24.1M | $2.3M | CVM | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CVM REV | BSEM REV | CVM GROSS % | BSEM GROSS % | CVM FCF | BSEM FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $47.5M | — | 93.6% | -$17.2M | $6.6M |
| FY 2024 | $0 | $69.7M | — | 80.3% | -$18.9M | $24.0M |
| FY 2023 | $0 | — | — | — | -$22.8M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CVM // BETA —
BSEM // BETA —